Questions in the chemical enzymology of MAO by Ramsay, Rona R. & Albreht, Alen
Review
Questions in the Chemical Enzymology of MAO
Rona R. Ramsay 1,* and Alen Albreht 2


Citation: Ramsay, R.R.; Albreht, A.
Questions in the Chemical
Enzymology of MAO. Chemistry 2021,
3, 959–978. https://doi.org/10.3390/
chemistry3030069
Academic Editors: Barbara De
Filippis and Gunter Peter Eckert
Received: 10 July 2021
Accepted: 28 August 2021
Published: 31 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Biomedical Sciences Research Complex, School of Biology, University of St Andrews,
St Andrews KY16 9ST, UK
2 Laboratory for Food Chemistry, Department of Analytical Chemistry, National Institute of Chemistry,
Hajdrihova 19, SI-1000 Ljubljana, Slovenia; alen.albreht@ki.si
* Correspondence: rrr@st-andrews.ac.uk; Tel.: +44-(0)-1334-474740
Abstract: We have structure, a wealth of kinetic data, thousands of chemical ligands and clinical
information for the effects of a range of drugs on monoamine oxidase activity in vivo. We have
comparative information from various species and mutations on kinetics and effects of inhibition.
Nevertheless, there are what seem like simple questions still to be answered. This article presents a
brief summary of existing experimental evidence the background and poses questions that remain
intriguing for chemists and biochemists researching the chemical enzymology of and drug design for
monoamine oxidases (FAD-containing EC 4.1.3.4).
Keywords: chemical mechanism; kinetic mechanism; oxidation; protein flexibility; cysteine modifica-
tion; reversible/irreversible inhibition; molecular dynamics; simulation
1. Introduction
Monoamine oxidase (E.C. 1.4.3.4) enzymes MAO A and MAO B are FAD-containing
proteins located on the outer face of the mitochondrial inner membrane, retained there
by hydrophobic interactions and a transmembrane helix. The redox co-factor (FAD) is
covalently attached to a cysteine and buried deep inside the protein [1]. Discovered as
tyramine oxidase [2], an enzyme that metabolized pharmacologically active amines such
as dopamine [3], MAO binds a range of small molecules, whose kinetic parameters are
shown in Table 1.
MAO became an important drug target when a tuberculosis drug was found to
improve the mood of patients. The large antidepressant market fueled the discovery of
other irreversible inhibitors of MAO [4–6] that act by covalent attachment [7–9]. The
common drugs such as selegiline (Table 1, used in the treatment of Parkinson’s disease)
modify the flavin, but binding to an amino acid residue was also reported for some
compounds [10,11]. The major side-effect of treatment with the irreversible inhibitors
is the tyramine-induced pressor “cheese effect” due to the inhibition of intestinal MAO
A that normally metabolizes dietary tyramine found at high levels in aged cheeses [12].
The treatment of depression then switched to re-uptake inhibitors and drug discovery for
MAO inhibition switched to reversible inhibitors, although the irreversible inactivators
of MAO still remain important for treatment of certain types of depression. Furthermore,
the increasing prevalence of neurodegenerative diseases has renewed interest in MAO
inhibitors (MAOI) that can conserve the decreased levels of monoamine neurotransmitters
in a deteriorating brain.
Although it is almost 100 years after the identification of monoamine oxidase, 70 years
after its adoption as a drug target and 20 years after its structure was solved, some inter-
esting questions still remain to be explored. These are outlined in this article as a starting
point for new investigations.
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Table 1. Some substrates, inhibitors and inactivators of MAO with their kinetic parameters.












137 228 Serotonin 1093 6.6
212 680 Dopamine 229 702
140 20 2-Phenylethylamine 4 309












0.028 Methylene Blue 5.5
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Table 1. Cont.











3.1 0.12 Phenelzine 50 a 0.9 a
7.7 0.78 Tranylcypromine 0.7 0.16
193 0.25 Selegiline d 0.1 0.53
9.7 0.007 Rasagiline b 0.7 0.05
0.03 1.8 Clorgyline 1.8 0.02
3.0 0.39 Contilisant e 4.6 0.19
Data: A from [13]; B summarized in [14] from references therein; C from [15] except a [16] and b [17]. c MPP+ is 1-methyl-4-phenyl-
pyridinium; d Selegiline is also known as L-deprenyl; e Contilisant is a multi-target compound which also inhibits cholinesterase and binds
to the histamine H3 receptor [18].
2. What Is the Chemical Mechanism of Amine Oxidation? Is It the Same for Both
MAO A and MAO B?
It is clear that MAO A and MAO B have different substrate and inhibitor selectivities
(for example, [13,19–21]) defined by the distinct hydrophobicity and binding site archi-
tectures, but the key region close to the FAD is the same [21]. The chemical mechanism
was substantially explored by traditional chemical approaches in the 1990s, but only four
mechanisms for oxidation of the amine by MAO have attracted major attention: single
electron transfer (SET), the polar nucleophilic mechanism or (as found in some other
FAD-dependent oxidases) hydride extraction, and a derivative thereof, two-step hydride
transfer [22] (see Figure 1). The strong chemical evidence for the single electron transfer
mechanism came from in depth studies on the inactivation of MAO by cyclopropylamines
and remains a probable mechanism for conversion of a cyclopropylamine into an activated
product capable of forming a covalent bond either to the FAD or to a cysteine [10,23].
However, inability to detect a flavin semiquinone radical by electron paramagnetic reso-
nance (EPR) during substrate turnover cast doubt on SET as the general catalytic pathway.
Quantum chemical calculations for a SET mechanism for para-substituted benzylamines
gave inverse correlation with experimental data, confirming that this is not the mechanism
of substrate oxidation [24].
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Figure 1. Chemical mechanisms proposed for MAO-catalyzed oxidation of amines.
In depth studies based on Hammett correlations were carried out in support of a
polar nucleophilic mechanism for MAO A where a convincing positive correlation of
oxidation rate with electronic effects of benzylamine substituents was obtained ($ = 2) [25].
In this study with MAO A, the more electron withdrawing character of the substituent,
the faster was the rate of oxidation, consistent with the polar nucleophilic mechanism
whereby a transient C4a adduct was formed with the flavin. In contrast, for MAO B, the
substituents that more efficiently stabilize the developing electron density in the transition
state slowed the rate, prompting the suggestion that MAO A and MAO B followed different
mechanisms [26]. However, although the slower rate of MAO B with electron withdrawing
substituents could be consistent with the hydride mechanism, nitrogen kinetic isotope
effects for the oxidation of benzylamine by MAO B showed that the rehybridization of
the N(5) nitrogen atom required for reduction of the flavin and the cleavage of the CH
bond for oxidation of the amine were not concerted [27]. A quantum mechanics/molecular
mechanics (QM/MM) study of benzylamine oxidation by the MAO also suggested that
the transfer of electrons and proton was asynchronous, supporting the polar nucleophilic
mechanism [28].
Hydride transfer was established for D-amino acid oxidase after high-resolution
structures with bound substrates were solved giving insight into the probable transition
state [29]. On the other hand, X-ray structures of MAO are available only with inhibitors
bound (see, for example, [30]), but since computational modeling based on these structures
became practical, evidence for a hydride transfer reaction in both MAO A and MAO B
has been mounting [31–34]. In a QM/MM simulation of the rate-limiting step for the
serotonin oxidation via hydride transfer to the N5 of the FAD in MAO A, the calculated
barrier was 14.8 ± 0.8 kcal mol−1, in good agreement with the experimental value of
16.0 kcal mol−1. The two-step hydride transfer mechanism shown for MAO B proposes
a hydride abstraction from the substrate and relaxation of the resulting flavin-substrate
adduct into a neutral amine and fully reduced flavin. The second part of the reaction
is presumably facilitated by two water molecules present at the binding site [34]. The
activation free energy for the hydride transfer in this computational study was shown to
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be roughly two-times smaller (24 kcal mol−1) than for any other oxidation mechanism by
MAO B.
Whether further experimental or modeling work would give clearer evidence for the
same hydride mechanism in both MAO A and MAO B is not certain. However, could two
enzymes with such similar catalytic sites support non-identical chemical mechanisms? Us-
ing Hammett correlations as in the example above has proved invaluable in many chemical
mechanistic studies. However, inductive and resonance effects of the substituents on the
aryl rings of reactants/substrates are rarely the only (although might be the prevailing)
factors governing the reaction kinetics. It has been demonstrated for MAO, for instance,
that steric hindrance in 2′-aryl substituted analogs of MPTP had a significant effect on the
determined Hammett values [35], and not only intramolecular but also intermolecular
steric effects and hydrophobic/hydrophilic interactions between the aryl substituents of
a reactant and its surrounding can be a source of deviation from linear Hammett plots
(e.g., [36–39]). These contributions to non-linearity are especially relevant when study-
ing mechanisms of enzymatic reactions since these take place within a tight binding site
where the degree of interactions of a particular substituent with amino acid residues of
the immediate surrounding can be considerable and distinct from that in the bulk solvent.
In the most severe cases, the rate-determining step or even the reaction mechanism itself
can change with the substituent [40,41]. Therefore, could the differing kinetic data (that
provide indirect insight into the catalytic mechanism of MAO) mostly reflect the steric
and/or other intermolecular interactions imparted by a distinct catalytic site (Figure 2)
which tilts the apparent activity of MAO A or MAO B to one or the other kinetic pattern in
an otherwise identical catalytic mechanism?
Figure 2. Small molecule binding in the active site of MAO A and MAO B. Representative binding
modes for the inhibitor 2-amino-5-(4-chlorophenyl)furan-3,4-dicarbonitrile bound to MAO A and
MAO B obtained from molecular dynamics simulations [42]. The inhibitor is shown as orange sticks
in MAO A and yellow sticks MAO B. Residues common to MAO A and MAO B are shown as blue
sticks, with the key “aromatic cage” tyrosines labelled in black (TYR). Residues that differ are shown
in green for MAO A and in magenta for MAO B and identified by the MAO A residue number
followed by the MAO B residue number. These residues have been reported to be important in
selectivity for small molecule binding. The flavin cofactor with the bent isoalloxazine ring is shown
as blue sticks for both MAO A and B.
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3. The Oxidative Half-Reaction: How Does Oxygen Access the Reduced Flavin, and Is
It Blocked or Facilitated by Ligands?
The regeneration of oxidized MAO, which completes MAO catalytic cycle, has been
less intensely studied. At a minimum, more experiments are needed to explain the very
different KM values for oxygen (MAO A at 0.06 mM but MAO B at 0.28 mM [43]). The
kinetics of oxidation of the amine substrate and the accompanying reduction of the FAD
in MAO have been studied in detail [44–48], but very little is known about how oxygen
accesses the reduced flavin to restore the oxidized FAD and produce hydrogen peroxide
(H2O2), the product of the second half-reaction and a potential cause of degenerative
effects [49].
In common with other oxidases, MAO has the FAD:N(5)-water-Lys (305 in MAO
A) motif thought to be key for oxygen activation [50]. By positioning oxygen in high
affinity sites, the likelihood of O2 reacting with the correct stereochemistry with FAD is
increased and generation of undesirable reactive oxygen species is minimized. The reaction
takes place between oxygen and the C4a position of the flavin. Key factors influencing
the reaction include accessibility, the distribution of charged and polar groups to favor
electron transfer between the two reactants, and the extent of stabilization of the C4a-
hydroperoxyflavin intermediate [51,52].
How does the oxygen get to the deeply buried site? In other oxidases, multiple
pathways have been identified [51]. Oxygen diffusion to the reduced co-factor is most
likely via tunnels that allow regulation of oxygen access [51]. Studies on MAO similar
to those that revealed multiple pathways in cholesterol oxidases [53] would be useful.
Could similar pathways in MAO provide insight into the substrate acceleration of re-
oxidation (see below)? Moreover, induced fit with substrate alters the O2 locations and
opens alternative channels [54]. Where are the oxygen access channels in MAO and does
substrate or product binding to reduced MAO change access or activation?
4. Kinetics: Can Simulation Explain the Alternative Pathways in Turnover; Why
Substrate Accelerates Oxidation and the Influence of Two Forms for
Binding Inhibitors?
4.1. Both the Oxidized and Reduced Forms of MAO Can Bind Ligands during Turnover
Early work varying both benzylamine and oxygen indicated a ping-pong mechanism
for rat MAO [55,56], but later kinetic studies demonstrated that some substrates followed
a ternary complex mechanism (Figure 3) [45,57,58]. Spontaneous hydrolysis of the imine
product to the aldehyde plus ammonia, at least some of which may occur in the active site,
complicates the picture [59]. However, hydrolysis of imine in the active site is probably
not the prevailing mechanism, but rather, it is primarily non-enzymatically hydrolyzed
outside the enzyme [60]. The number (and orientation) of water molecules in the active
site depends on the particular isozyme (MAO A versus MAO B) and the nature of the
substrate [49,61,62]. Many water molecules can be of structural type (e.g., involved in
hydrogen bonding), making them very unlikely to take part in any type of reaction [63].
Nonetheless, imine hydrolysis in the active site can still be considered plausible. Aldehydes
are very poor uncompetitive inhibitors [60] so can be considered to dissociate easily, but
does ammonia dissociate more slowly? With a pKa of ammonia being 9.2, it is not difficult
to imagine a proton abstraction by ammonia from an acidic amino acid residue in the active
site, resulting in a protonated species which can be effectively “trapped” by favorable
cation-π interactions with the tyrosine residues that constitute the “aromatic cage” [63,64].
From results using a benzylamine analog oxidized to a spectrally distinct imine product, it
has been argued that the reduced enzyme-imine complex is reoxidized before the bound
imine signal is lost [59]. If either ammonia or imine remained bound, free reduced enzyme
would be minimal, and no new ligand could bind. However, the kinetics demonstrating
binding of inhibitor to reduced enzyme indicate that free reduced enzyme is present during
turnover [57,58,65].
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Figure 3. Alternative pathways for oxidation complicate MAO kinetic studies.
Ultimately, whether a pool of free reduced enzyme builds up during turnover will
depend on the rate constants for the half-reactions, the concentrations of the substrates
(amine and oxygen), and the affinities of the oxidized (Eo) and reduced (Er) forms of the
enzyme for their ligands (see Figure 3). Although reduction of the FAD by the amine
substrate is the slowest step in the reaction catalyzed by MAO, there are three possible
pathways for the reoxidation of the reduced FAD co-factor. The rate of reoxidation of the
reduced MAO B without ligand is slow (kox, 1.8 s−1 at 0.28 mM oxygen) and whether Ered-P
is oxidized before dissociation of the imine product is questioned. When some substrates
are preincubated with reduced MAO, the rate of oxidation increases 2–100 times [45]; so
for those substrates, the pathway in the green box dominates. Based on data from [45],
2-phenylethylamine (PEA) reduces bovine MAO B at 572 s−1 (kred), rapidly generating Ered,
but the steady-state turnover rate is 3.6 s−1. The imbalance in rates means that the MAO
is mostly reduced (Ered) during steady-state oxidation of PEA. Based on steady-state and
half-reaction studies, oxidation of PEA is mainly via the binary pathway. With benzylamine
as substrate, the reduction and reoxidation rates are similar (10.9 and 7.6 s−1, respectively),
and reoxidation is mainly via the ternary complex pathway indicated by the green rectangle.
It should be noted that reoxidation rates are influenced by the concentration of oxygen
([O2]). Even with these similar rates of reduction and oxidation, some intermediate Ered
is available for binding of inhibitor as has been demonstrated in bovine MAO B [57] and
for human MAO B [65]. That the affinities of the oxidized (Eo) and reduced (Er) forms
of the enzyme for inhibitors can differ was demonstrated for the tricyclic antidepressant
amitriptyline which gives a Ki of 0.5 mM with Eo but 2.5 mM with Er [66]. The question
is important for the drug design process because IC50 measurements used to screen new
compounds will vary with the proportion of reduced enzyme present during turnover
which depends upon the assay and substrate used [65,66].
The occurrence of differential binding to Eo and Er was established by in-depth kinetic
investigations in vitro [65]. In laboratory assays, the O2 concentration in buffer at 30 ◦C
(0.22 mM) is below the KM for O2 with MAO B (0.28 mM) [43], and the oxygen content
drops with temperature. Although the kinetic isotope effects in air-saturated buffer (21.1%
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or 101.3 kPa oxygen) of 5–10 show that amine oxidation is the slower step [46], the rate
of reoxidation at sub-saturating oxygen conditions will influence turnover more as the
oxygen concentration decreases below its KM, especially at low substrate (amine) levels.
(See more information on the kinetics of oxidation below.) In cell culture at 37 ◦C and 21%
oxygen, a dissolved extracellular concentration of 0.21 mM was measured, but depending
on conditions, oxygen concentration intracellularly was only 0.175 mM [67]. However, this
is now considered hyperoxia rather than physiological normoxia. Human tissues have
oxygen concentrations varying around 6%, but inside the cell, it is 1.3–2.5% [67], one-tenth
of that for in vitro experimental concentrations. Could simulations explore MAO kinetics
and redox status (proportions of Eo and Er) in the brain?
4.2. Substrate Stimulation of Reoxidation-Thermodynamic or Kinetic?
That the slowest step in the MAO reaction is the reductive half-reaction (oxidation
of substrate amine to imine) is clear from studies involving deuterated substrates where
large kinetic isotope effects of 5–14 were obtained [25,46,48,68–71]. However, the oxidative
half-reaction of MAO measured in isolation is slower than the observed steady-state
turnover rate for many substrates [45]. By pre-incubating chemically reduced MAO with
substrate before rapidly mixing it with oxygen, it was demonstrated that the substrate
stimulates the rate of reoxidation, whereas, for MAO A, a product (MPP+) or an inhibitor
(D-amphetamine) inhibit the rate. Moreover, different substrates give different increases
in the slow rate of reoxidation of free reduced enzyme (1 s−1) found with both MAO A
and MAO B. For MAO A with kynuramine, the rate of flavin re-oxidation was 120 s−1,
with benzylamine 23 s−1 and with MPTP 40 s−1. For MAO B, the rate of re-oxidation of
the flavin in enzyme saturated with kynuramine was 2.2 s−1, benzylamine 7.6 s−1, and
MPTP 6.0 s−1 [45]. Therefore, is it the imine or ammonia still bound that facilitates the
oxidation (although MPP+ clearly inhibits) or does the binding of new substrate to the
reduced enzyme govern the kinetics of oxidative half-reaction? Inhibition kinetics [57] do
show that free enzyme is available before re-oxidation of the reduced flavin, so perhaps
substrate acceleration is the dominant pathway for the normal substrates, but how is the
effect achieved?
Measurement of the redox potential of the reductive half-reaction for MAO A in the
absence and presence of substrate suggested that substrate increased the redox poten-
tial [72] but similar experiments in MAO B did not [73]. A change in redox potential would
indicate a change in the conformation or environment of the FAD, but it is more likely
that the reported MAO A change was due to lack of equilibrium between the dye and
FAD. However, the environment of the flavin has long been known to influence the redox
potential [74], and substrate (or inhibitor) binding is likely to alter that environment. In-
deed, the shifts in the circular dichroism spectrum indicated differences in the FAD region
when substrate was added [75]. The differences between the oxidized and reduced circular
dichroism spectra also indicate a change in the FAD environment or shape (see below).
5. Is There Potential for Applied Use of MAO?
MAO turnover is slow (3–10 s−1 [45]) but specific (the pro-R hydrogen from the α
carbon next to the amine is removed [76]). Tighter substrate cavity of MAO B results
in increased steric hindrance and in distinctive amino acid residue interactions with
small molecules. This makes MAO B more sensitive to the absolute configuration at
chiral centers of enantiomeric substrates and inhibitors [20] with potential for high value
chemical synthesis.
Specificity is also governed by hydrophobic and hydrophilic regions of the cavity.
The environments of both substrate cavities are generally hydrophobic, but MAO B is
slightly more so. Consequently, by transforming some regular MAO B inhibitors into
quaternary ammonium salts, selective MAO A inhibitors were obtained [77]. Within
each cavity, docking of variants within the many classes of inhibitors has demonstrated
the importance of specific interactions such as hydrogen bonding. Specially, MAO A
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Phe208-Ile335 and MAO B Ile199-Tyr326 pairs (see Figure 2) were suggested to be major
determinants which govern the differential inhibitor specificities of the two isozymes [78].
Site-directed mutagenesis studies showed that Ile335 in MAO A and Tyr326 in MAO B are
key amino acid residues determining substrate and inhibitor specificities in human and
rat MAO A and B [79–81]. By tempering with these two residues, the spatial and chemical
architecture of the substrate cavity is altered, and MAO B selectivity starts to mimic that of
MAO A and vice versa. A change in selectivity was also induced by the single mutation
Phe208 to Ile199 [82]. However, the wide range of effective inhibitors demonstrates that
affinity for a ligand is determined by multiple interactions within the large cavity (for
examples, see recent reviews: [83–85]).
Purified MAO is not stable enough for most applications, but MAO electrodes in-
corporating membrane-bound MAO have been devised for measurement of amines, for
example, for serotonin using MAO A [86,87]. For electrode use, an alternative to oxygen
as the electron acceptor in the oxidative half-reaction is desirable. Methylene Blue and
similar dyes are known acceptors [88,89], but performance could be improved by rational
engineering of the oxygen pathway or reaction site [90]. This has been demonstrated for
MAO A by mutating Lys305: after reduction by serotonin, the K305M MAO A reoxidation
by oxygen was much slower but electrons could pass instead to a quinone [91].
In contrast to the mitochondrial MAO, the Aspergillus niger enzyme, MAO N is more
tractable for protein engineering and large-scale production although the FAD is not
covalently bound to the enzyme [92–94]. MAO N is suitable for chiral catalysis and use of
whole cells avoids the limitation of FAD supply [95,96]. Whole cell methodologies might
be the best way forward for any use of mitochondrial MAO, but tuning MAO N to the job
seems the better option.
Perhaps also of interest for applications in biological tissues or in vivo is the obser-
vation that geometric isomers of cis- and trans-1-propargyl-4-styrylpiperidine distinguish
between MAO A and MAO B. The cis isomers are potent human MAO A irreversible
inhibitors whereas the trans analogues inactivate only MAO B both in vitro and in mouse
brain [97].
Overall, drug design remains the major applied opportunity for treatment of depres-
sion, neurodegeneration or cancer [98]. Identification of key interactions at the catalytic
site fuels innovation towards new lines of MAO inhibiting drugs with enhanced selectivity
and potency.
6. Importance of Flexibility
6.1. Is Flexibility Important in the Reaction?
Crystal structures present a frozen view of enzymes, but from this accurate foundation,
rapidly advancing computational approaches reveal a much more dynamic nature of en-
zymes in their physiologic environment, including, for MAO, at the interface of the cytosol
and the mitochondrial outer membrane. Experimentally, MAO flexibility is seen as changes
in the circular dichroism spectra of both flavin and aromatic amino acid environments after
ligand binding or redox change [75]. An early modeling test (on the MAO B structure from
which the reversible inhibitor, isatin, had been removed) fixing the amino acids around
the flavin indicated no hindrance to flattening of isoalloxazine ring from the 30◦ bend seen
in the crystal structure of the enzyme-bound flavin [99]. The isoalloxazine ring in many
flavoproteins changes from flat to a bent ring upon reduction, but all crystal structures
of MAO whether oxidized (reversible inhibitor bound) or reduced (irreversible inhibitor
attached to the FAD) show a 30◦ bend along the N(5)-N(10) axis [78]. It is hypothesized that
this strain at the coenzyme binding site may have catalytic relevance, mainly increasing
the nucleophilicity of N(5) and electrophilicity of C(4a) [100]. Any movement of FAD or
protein residues could also alter the oxygen accessibility, crucial for MAO turnover. If
structural perturbations could be used effectively to steer the electronic characteristics of
the cofactor and thus regulate the catalytic activity, why does flavin in MAO A and MAO B
adopt a bent position in crystals regardless of its redox state?
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Turning to the flexibility of the protein, induced fit within the active site is evidenced
by the slow onset of full inhibition by larger reversible inhibitors (even 1-methyl-4-phenyl-
pyridinium (MPP+) for which perturbation of the flavin spectrum showed an on-rate of
108). Slow on (30 min) and off (6 washes) rates were also observed in reversibility experi-
ments with safinamide [101]. Molecular dynamics now confirm considerable movement in
active site in addition to alternate binding modes obtained by docking. Enzyme tertiary
structure adjustments of the active site environment are also necessary to accommodate the
irreversibly bound inhibitors, which cannot adopt the most stable structural conformation
otherwise [102]. Therefore, what constitutes the line between MAO flexibility and rigidity
allowing for a number of structurally distinct (but related) substrates to be oxidized by the
enzyme while assuring that certain biological functions are properly regulated on account
of substrate specificity?
Flexibility (and rigidity) could also be important for crosstalk between the monomers
in the MAO dimer. Pulsed electron paramagnetic studies demonstrated that both MAOs
from human and rat are dimeric in the membrane [103]. Does dimer crosstalk play a role
in kinetics or in ligand binding? Although there was some speculation in older literature
about occupancy of one site changing the activity of the other, this topic needs evidence.
6.2. The Influence of the Membrane on MAO Activity
Simple steady-state kinetic experiments showed that membrane-bound MAO gave a
lower KM for some substrates compared to purified enzyme. For example, MAO A had a 10-
fold lower reversible Ki for clorgyline [104]. In experiments studying solvent accessibility
to the active site using spin-labeled derivatives of the inactivator, pargyline, no difference
between detergent-extracted and membrane-bound MAO was found [105]. However,
lower Ki values for the initial reversible inhibition of MAO by propargylamine inactivators
in membrane preparations was demonstrated in kinetic studies. The close association
of MAO with the membrane and the close proximity of the entrance to the active site to
the membrane surface might be expected to influence the dynamics of substrate access
or product exit due to steric hindrances and the flexibility of the substrate entrance loop
(residues 99–112) [106,107]. When this question was examined using molecular dynamic
simulations, effects were indeed found. The membrane influenced the fluctuations of
two loops at the entrance to the active site cavity (residues 85–110 and 155–165 in MAO
B) [108]. Membrane control of the active site access was reinforced by the differences in the
temperature-dependence of benzylamine oxidation by MAO B between purified enzyme
and the same enzyme attached to nanodiscs [109]. (However, it should be noted that the
preparation used for these experiments had a completely different spectrum from MAO
B purified in at least three other laboratories.) Exploring the influence of the membrane
using long molecular dynamic simulations, the same authors looked for oxygen tunnels
leading to the FAD and found two entrances, one on each side of the gating loop (residues
99–112). Residues at both entrances are closely associated with the membrane. Given the
insight from these computational studies, new investigation of previously observed lipid
effects on rat mitochondria MAO could provide further understanding of the importance
in vivo [110–114]. Could alterations in the membrane composition (from diet, for example)
have consequences for activity, raising or lowering the monoamine pool in the brain?
6.3. Does the Oxidation of MAO Thiols Have Any Importance In Vivo?
Continuing the theme of biological influence from chemical changes, do the solvent
accessible cysteines influence activity? Both MAO A and MAO B form a covalent 8α-
thioether linkage with the flavin (at Cys407 and Cys398, respectively) and contain 8 other
cysteine residues in reduced (SH) form. Although 7 of the 9 cysteines are in conserved
sequence locations, only MAO B has one that interacts with ligand in the active site
(Cys172) [115,116]. Free thiol groups in proteins are subject to various modifications from
reaction with reactive species generated by mitochondria [117,118] and thiol modification
can both regulate and damage cell function [119]. Although located on the cytosolic
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surface of the mitochondrial outer membrane, the 8 modifiable cysteines in MAO [120–122]
are close to the greatest cellular source of reactive oxygen species, the electron transport
chain on the inner membrane. The initial study where each Cys was mutated to serine
demonstrated individual effects of each on MAO activity. Most of the mutants behaved like
the wild-types, but complete loss of activity was observed for MAO A Ser374 and MAO B
Ser156 and Ser365 mutants [123]. Later, Cys365 was labeled specifically during inactivation
of MAO B with N-cyclopropyl-N-α-methylbenzylamine, indicating its involvement in
the inhibitory pathway [124]. The equivalent Cys374 in MAO A substituted with alanine
gave kcat/KM values 30% lower than for the wild type [122]. Chemical modification of
the thiols revealed different susceptibility: MAO A was more rapidly inactivated by N-
ethylmaleimide (half-life about 3 min) than MAO B (half-life about 8 h) [121]. Moreover,
Cys266 and Cys5 seem to be the only two thiols modified in clorgyline-inactivated MAO
A and pargyline-inactivated MAO B, respectively, which demonstrates that inhibitors, as
well as substrates, stabilize the enzyme structure and increase the rigidity [116]. Does
occupancy of the active site by the amine substrate prevent oxidation of cysteine residues
in mitochondrial MAO and to what extent?
The presence of reactive oxygen species around mitochondria in the cell can oxidize
protein thiols in the vicinity, so thiol modification could be significant for catalysis under
physiological conditions. Further development and application of chemical methods to
detect, distinguish, and time modify cysteines in the cell or tissues would allow better
understanding of any consequences from modifications of cysteines in MAO [119,125,126].
7. Biological Questions
7.1. Does Variation in the Calcium Ion Concentration Change MAO Activity?
In neurons, ion fluxes during the action potential result in transient changes in the
calcium ion concentration in the cytosol, but uptake by the endoplasmic reticulum and
mitochondria quickly restore the normal low micromolar level. Calcium (Ca2+) was found
to increase MAO activity in mitochondria and cells [127–130]. When a short burst of
Ca2+ was induced in mice by a calcium channel agonist, the increase in MAO A activity
was transient [130]. In vitro, preincubation of membrane-bound hMAO with 1 mM Ca2+
increased the MAO A maximum velocity 2-fold but did not change MAO B [131]. No other
divalent cation increased activity but zinc ion was strongly inhibitory. More physiologically
relevant, a 20% increase in activity was observed when Ca2+ was increased from 10 nM
to 10 uM, the normal range for calcium signaling. How does Ca2+ exert this influence
on activity? Is the ion size the determining factor? Why is only MAO A activated? A
calcium-sensitive increase in MAO A activity increased the production of peroxyradicals in
hippocampal cultures, and this was postulated to have implications for neuronal damage
in Alzheimer disease [132]. Is this calcium-sensitive stimulation of MAO A activity increase
relevant in the cell and in pathology?
7.2. Does MAO A Moonliaght in the Cell?
MAO metabolizes neurotransmitter amines in nervous tissue and biogenic amines
in all cells so that alterations in activity alter signaling amine levels. Sustained changes in
monoamine levels trigger adaptations in levels of other proteins, including receptors. For
MAO A itself, putative non-catalytic roles for the protein have been proposed, involving ei-
ther direct protein-protein interaction or a signaling relay influencing gene expression. The
association of some Alzheimer’s disease (AD)-related presenilin-1 variants with depression
led to studies that demonstrated a direct interaction between presenilin-1 and MAO A
proteins and a change in MAO A activity [133,134]. MAO A knockout mice revealed the
importance of serotonin and MAO A in apoptosis during brain development [135]. MAO
A levels are influenced by both genetic and environmental factors, and MAO A activity
influences psychopathologies [136,137]. The anorexigenic hormone leptin that protects
mitochondrial function regulates the expression and activity of MAO B [138]. Leptin also
reduced the increase in MAO A and MAO B expression found in hippocampal neurons
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treated with the Alzheimer’s disease peptide Aβ. In Alzheimer’s disease, which leads
to cell loss in the brain, an increase in MAO B was evident but MAO A also increased
in some regions. Intriguingly, co-regulation of MAO A and MAO B levels observed in
normal post-mortem brains was lost in the hippocampus but not in the cortex of Alzheimer
brains [139].
When MAO A activity in human neuroblastoma cells was knocked down to about
30% that of control cells, ATP was increased, reactive oxygen species were decreased, and
the cells were protected against apoptosis. The effects were linked to electron transport
because although inhibition of electron transport up-regulated MAO A in control cells, the
low MAO A activity in the knock-down cells protected mitochondria from inhibition [140].
Although a genomic study found MAO A to be down-regulated in some cancers [141], it
is clearly elevated in aggressive prostate cancer and classical Hodgkin’s lymphoma [142,143].
A small Phase 2 clinical trial found that the irreversible MAO inhibitor, phenelzine, suc-
cessfully decreased markers of prostate cancer, opening a new application for MAO A
inhibitors [144].
Keeping in mind the location of MAO at the interface between the cytosol and mito-
chondria, untangling the many interactions for MAO and the network of signaling and
gene expression will require considerably more cellular and genetic research.
7.3. Species Differences and Mutations?
Kinetic studies identified differences in inhibitor binding to MAOs from different
species [145–149]. Although mammals all have two forms of MAO, fish have only one [150].
After the structures of MAOs were published, a detailed examination of the kinetics and
structures of MAOs from rat and human provided better understanding of the differ-
ences [105,151]. With different types of cells used in many pharmacological and toxicology
studies, researchers should be aware also of differential expression of MAO A or B in each
cell type [152]. The question in this section is curiosity-driven: species differences are seen
in the active sites of MAO A and MAO B, but human mutations altering active site amino
acid residues to influence activity or ligand binding have not been identified from clinical
studies. Known human variants identified by genetic studies are sequence repeats that
alter expression levels with behavioral consequences [153–157].
One theoretical study has provided the basis for a lower activity based on a mutation
in the middle of the MAO B active site. When tyrosine 326 in MAO B is changed to
isoleucine (as found in MAO A-so the mutant oxidizes serotonin better), the activity (kcat)
with phenylethylamine dropped to 27% of the wild-type, and the KM increased [79]. When
the oxidation of the amine was simulated, reaction free energy profiles showed that the
barrier in the mutant was 1.06 kcal mol−1 higher, due to loss of electrostatic interactions
and dielectric shielding [158]. Are there similar variants in the human populations and
could new experiments and clinical studies demonstrate consequences of the lower activity
giving higher amine levels in the brain for human behavior?
7.4. The Pharma Debate-Reversible or Irreversible Inhibition?
The effect of a successful drug is governed by binding affinity and by pharmacokinetics.
For a high affinity reversible inhibitor, side effects should be low, and the inhibition is easily
reversed. Indeed, it might be desirable that a surge in the amine substrate concentration
would out-compete the inhibitor. For irreversible inhibitors, reaching a steady-state level
of inhibition might take longer if the dose is low, but the effect would persist until the
inactivated enzyme was replaced by a new protein molecule.
To achieve the desired clinical effect in depression or Parkinson’s disease, MAO
inhibition must be greater than 75% [159]. Despite the rapid inhibition of MAO that would
occur in vitro (immediate for reversible inhibitors and minutes for irreversible inhibitors)
and the detection of MAO using 11C-deprenyl in positron emission tomography (PET)
scans recorded from 25 min after the infusion [160], clinical improvement is slow [161].
At the end of treatment, a “wash-out” period of three weeks is recommended for the
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irreversible inhibitors to allow the synthesis of new protein, so activity resumes at the slow
pace of turnover-the half-life of MAO B in baboons was measured by PET using labeled
L-deprenyl as 30 days [162]. For reversible inhibitors, clearance of the drug from circulation
should result in rapid return of MAO activity, but a minimum of two weeks washout is
still recommended.
The question of whether a reversible MAOI or an irreversible MAOI provides better
treatment has mostly been investigated for Parkinson’s disease for which the irreversible
selegiline (or the similar drug, rasagiline) and the reversible safinamide are commonly
used to delay the need for levodopa (L-dopa) treatment. Selegiline has neuroprotective
effects [163] and antidepressant action, but tyramine potentiation fears and dietary re-
strictions persist, except for the transdermal form. Safinamide has other effects beneficial
against PD including blockage of voltage-dependent sodium channels and has low tyra-
mine potentiation [164]. When reversible and irreversible inhibitors are compared, both
have been found to be effective as adjuvant therapy to delay or reduce the need for L-
dopa [165]. However, a meta-analysis comparing MAOI alone or with L-dopa showed that
selegiline was the most effective drug and that both it and rasagiline were more effective
than safinamide (selegiline > rasagiline > safinamide) [166].
Further study of clinical outcomes with irreversible versus reversible inhibitors in
depression would also be useful. Reuptake inhibitors are first choice for depression, then
reversible MAOI, while irreversible inhibitors are used when other treatments fail. This
is partly due to the side effects that require dietary restrictions but probably more due to
inexperience with these drugs [167,168]. Certainly for Parkinson’s disease, prescribing
habits vary from country to country [165].
Much recent effort has gone into designing reversible MAOI, especially for MAO B and
Parkinson’s disease. Many scaffolds are used, but particularly successful compounds have
been found amongst coumarin derivatives, which are competitive inhibitors with inhibition
constants as low as 0.25 nM [169–172]. However, what if irreversible inhibitors provide
more stable inhibition of MAO, especially in contrast to drop in inhibition unless there
is strict compliance with the dosing regimen for reversible drugs? Certainly, multi-target
compounds designed for use in multi-factorial neurodegeneration such as Alzheimer’s
disease have employed the propargylamine moiety to give irreversible MAO inhibition
leaving more flexibility to adapt the rest of the molecule to give high affinity binding to
other targets such as the cholinesterases. For example, the propargylamine moiety for MAO
inactivation has been combined with inhibition of the cholinesterases and antagonism
at histamine H3 receptors in one molecule with suitable drug-like properties [18,173].
However, do these multi-target species really “outperform” a drug mixture composed of
individual inhibitors in clinical use?
Therefore, what should drug research for MAO seek: reversible or irreversible? It is
still a debate, but the original irreversible classes on MAO inhibitor drugs are still an essen-
tial part of clinical practice, with the reversible drugs appearing somewhat less effective.
8. Conclusions
After 100 years of research on the MAO enzymes and 60 years on the MAOI, there re-
main still interesting questions to explore for neurologists, pharmacologists, enzymologists,
computational experts and chemists. Have fun!
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